期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 79, 期 3, 页码 311-327出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2021.09.013
关键词
-
The Kidney Disease Outcomes Quality Initiative (KDOQI) work group reviewed the 2021 KDIGO guideline for blood pressure management in chronic kidney disease (CKD), emphasizing the importance of accurate assessment and providing recommendations for target systolic blood pressure. However, they found weak evidence base for patients with diabetes and advanced CKD.
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recommendations and practice points from the KDIGO guideline in the context of US clinical practice. A critical addition to the KDIGO guideline is the recommendation for accurate assessment of blood pressure using standardized office blood pressure measurement. In the general adult population with CKD, KDIGO recommends a goal systolic blood pressure less than 120 mm Hg on the basis of results from the Systolic Blood Pressure Intervention Trial (SPRINT) and secondary analyses of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. The KDOQI work group agreed with most of the recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据